论文部分内容阅读
目的:观察华蟾素对人胰腺癌CFPAC-1细胞系裸小鼠移植瘤的抑瘤作用及血清白细胞介素6(IL-6)、白细胞介素8(IL-8)和可溶性血管细胞黏附分子1(sVCAM-1)表达水平的影响。方法:将体外培养的人胰腺癌CFPAC-1细胞接种于40只裸小鼠右前肢腋下皮下,建立荷瘤模型。造模成功后随机分为模型组、卡培他滨组、华蟾素低、高剂量(25,50 g.kg-1)组,每组10只,分别采用含阿拉伯胶的柠檬酸缓冲液、卡培他滨混悬液及华蟾素药液灌胃。治疗5周后,眼眶取血,酶联免疫吸附(ELISA)法检测血清IL-6I,L-8s,VCAM-1含量;脱颈椎处死裸小鼠,剥取肿瘤,称取质量,计算抑瘤率。结果:华蟾素各组CF-PAC-1裸鼠移植瘤质量下降,与模型组比较,差异有显著统计学意义(P<0.01)。高、低剂量华蟾素组裸鼠血清IL-8水平显著低于模型组(P<0.01),且低剂量华蟾素组和卡培他滨组血清sVCAM-1水平显著低于模型组(P<0.01),高剂量华蟾素组血清IL-6水平显著低于模型组(P<0.01)。结论:华蟾素对裸小鼠胰腺癌移植瘤模型有明显的抑瘤作用,其作用机制可能与下调细胞因子IL-6I,L-8和sVCAM-1的表达有关。
OBJECTIVE: To observe the antitumor effect of cinobufacini on human pancreatic cancer CFPAC-1 cell line xenografted nude mice and the effects of interleukin 6 (IL-6), interleukin 8 (IL-8) and soluble vascular cell adhesion Effect of sVCAM-1 expression level. Methods: Human pancreatic cancer cell line CFPAC-1 was inoculated subcutaneously in the right forelimb of 40 nude mice to establish a tumor-bearing model. The rats were randomly divided into model group, capecitabine group, cinobufotalin low dose and high dose (25,50 g.kg-1) group, 10 rats in each group. The rats were treated with acacia-containing citrate buffer , Capecitabine suspension and cinobufacini liquid gavage. Serum IL-6I, L-8s and VCAM-1 levels were detected by orbital bleeding after 5 weeks of treatment. Nude mice were sacrificed by cervical dislocation, the tumor was stripped, weighed, and the anti-tumor rate. Results: The quality of xenografted CF-PAC-1 xenografts in nude mice decreased significantly compared with the model group (P <0.01). The levels of serum IL-8 in high and low dose cinobufotalin groups were significantly lower than those in model group (P <0.01), and the levels of sVCAM-1 in low dose cinobufotalin and capecitabine groups were significantly lower than those in model group P <0.01). Serum IL-6 level in high-dose cinobufacini group was significantly lower than that in model group (P <0.01). CONCLUSION: Cinobufacini can significantly inhibit tumor growth in nude mice, which may be related to down-regulation of cytokines IL-6I, L-8 and sVCAM-1.